Godavari Drugs Limited Issues Clarification on Share Price Movement to BSE

Godavari Drugs Limited has responded to a BSE inquiry regarding significant movement in its share price and trading volume, confirming that no unpublished price sensitive information exists that could influence the stock's performance.

Regulatory Response to BSE Inquiry

In a formal communication dated January 8, 2026, the pharmaceutical company addressed the BSE's request for clarification on the notable price and volume movement in its securities. The company's response was signed by Venkatesh Achanta, Company Secretary and Compliance Officer.

Company's Official Position

Godavari Drugs Limited confirmed that it does not possess any unpublished price sensitive information (UPSI) as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company emphasized that no information requiring disclosure to stock exchanges exists that could have influenced the movement in price or volume of its securities.

The company highlighted its commitment to maintaining adequate internal controls and robust corporate governance practices to ensure compliance with applicable laws and prevent unauthorized dissemination of information.

Market Movement Attribution

The pharmaceutical company clarified that the movement in its share price and trading volume appears to be purely market-driven, based on demand and supply factors beyond the company's control. The management stated it is not in a position to comment specifically on the reasons for such market movement, given that the shares are freely traded on stock exchanges.

Regulatory Compliance Assurance

Godavari Drugs Limited reaffirmed its consistent compliance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including Regulation 30. The company provided assurance that it will continue to make all required disclosures in a timely manner as and when applicable.

The company requested the BSE to take the clarification on record, demonstrating its commitment to transparent communication with regulatory authorities and maintaining investor confidence through proper disclosure practices.